Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...

INGELHEIM, Germany, April 2 (Reuters) - Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug ...

Germany’s Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung ...

The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines), Inc. the prestigious Presidential Service Award during the Annual Convention Opening Ceremony on April 24, 2025, ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines) Inc. the prestigious Presidential ...

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a ...

Ingelheim, Germany, 22 May 2025 – Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune ...

The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients ...

INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license ...

Brian Hilberdink, a pharmaceutical industry veteran, recently assumed the role of President, U.S. Human Pharma, at Boehringer Ingelheim. Hilberdink recently sat down for an informal Q&A on his new ...